Sarepta Therapeutics, Inc. (BMV:SRPT)

Market Cap	32.74B
Revenue (ttm)	46.80B
Net Income (ttm)	-1.09B
Shares Out	n/a
EPS (ttm)	-11.29
PE Ratio	n/a
Forward PE	9.42
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	4,330
Open	328.01
Previous Close	350.00
Day's Range	328.01 - 334.79
52-Week Range	198.74 - 2,501.45
Beta	n/a
RSI	48.98
Earnings Date	Aug 6, 2025

About Paramount Global

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat Duchenne muscular dystrophy (Duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1980
• Employees: 1,372
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: SRPT